CYP — Cynata Therapeutics Share Price
0.000.00%
Last trade - 00:00- AU$37.72m
- AU$26.55m
- AU$0.35m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.07 | ||
| Price to Tang. Book | 3.67 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 86.47 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -113.31% | ||
| Return on Equity | -87.15% | ||
| Operating Margin | -3187.03% | ||
Financial Summary
| Year End 30th Jun | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 0.19 | 0.07 | 0.08 | 7 | 0.35 | n/a | n/a | 19.81% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.
Directors
- Geoffrey Brooke CHM
- Ross Macdonald CEO
- Kilian Kelly COO
- Suzanne Lipe VPR
- Stewart Washer NED
- Paul Wotton NED (60)
- Darryl Maher NID
- Last Annual
- June 30th, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- March 12th, 2003
- Public Since
- December 20th, 2007
- No. of Shareholders
- 3,317
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Australian Stock Exchange - SEATS
- Shares in Issue
- 179,631,786
- Address
- Level 3, 100 Cubitt Street,, Cremorne, MELBOURNE, 3121
- Web
- https://www.cynata.com/
- Phone
- +61 370676940
- Auditors
- Stantons International Audit and Consulting PTY Ltd
Upcoming Events for CYP
Similar to CYP
Actinogen Medical
Australian Stock Exchange - SEATS
Adalta
Australian Stock Exchange - SEATS
Algorae Pharmaceuticals
Australian Stock Exchange - SEATS
Alterity Therapeutics
Australian Stock Exchange - SEATS
Amplia Therapeutics
Australian Stock Exchange - SEATS
FAQ
What is the Cynata Therapeutics share price?
As of Today at 19:06 UTC, shares in Cynata Therapeutics are trading at AU$0.21. This share price information is delayed by 15 minutes.
How has the Cynata Therapeutics share price performed this year?
Shares in Cynata Therapeutics last closed at AU$0.21 and the price had moved by +5% over the past 365 days. In terms of relative price strength the Cynata Therapeutics share price has outperformed the ASX All Ordinaries Index by +0.43% over the past year.
What are the analyst and broker recommendations for Cynata Therapeutics?
The overall consensus recommendation for Cynata Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Cynata Therapeutics dividend yield?
Cynata Therapeutics does not currently pay a dividend.
Does Cynata Therapeutics pay a dividend?
Cynata Therapeutics does not currently pay a dividend.
When does Cynata Therapeutics next pay dividends?
Cynata Therapeutics does not currently pay a dividend.
How do I buy Cynata Therapeutics shares?
To buy shares in Cynata Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Cynata Therapeutics?
As of the previous close price of AU$0.21, shares in Cynata Therapeutics had a market capitalisation of AU$37.72m.
Where are Cynata Therapeutics shares listed?
Here are the trading details for Cynata Therapeutics:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: CYP
What kind of share is Cynata Therapeutics?
Based on an overall assessment of its quality, value and momentum Cynata Therapeutics is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Cynata Therapeutics share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the Cynata Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cynata Therapeutics. Over the past six months, its share price has outperformed the ASX All Ordinaries Index by +38.44%.
As of the last closing price of AU$0.21, shares in Cynata Therapeutics were trading +44.28% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Cynata Therapeutics PE Ratio?
The Cynata Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at AU$0.21.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Cynata Therapeutics?
Cynata Therapeutics' management team is headed by:
- Geoffrey Brooke - CHM
- Ross Macdonald - CEO
- Kilian Kelly - COO
- Suzanne Lipe - VPR
- Stewart Washer - NED
- Paul Wotton - NED
- Darryl Maher - NID